C5-PARK2-KO
The cell line is not validated yet.
GIBHi002-A-1
General
Cell Line |
|
| hPSCreg name | GIBHi002-A-1 |
| Cite as: | GIBHi002-A-1 (RRID:CVCL_YC27) |
| Alternative name(s) |
C5-PARK2-KO
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
GIBHi002-A (C11) STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease STBCi026-A-1 (SFC840-03-03 LRRK2-/-D10) STBCi026-A-2 (SFC840-03-03 LRRK2-/-C11) STBCi026-A-3 (SFC840-03-03 LRRK2 WT/R1441C H3) BIONi037-A-1 (16423 ApoE KO) WAe009-A-1P (IsoHD-30Q-NGN2) WAe009-A-1Q (IsoHD-65Q-NGN2) WAe009-A-1R (IsoHD-81Q-NGN2) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) BIONi037-A-2 (BIONi037-A ApoE2/2 #M10-7) BIONi037-A-3 (BIONi037-A ApoE3/4 #P10-22) BIONi037-A-4 (BIONi037-A ApoE4/4 #I10-53) |
| Last update | 17th October 2019 |
| User feedback | |
Provider |
|
| Generator | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH) |
| Owner | Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH) |
| Distributors | |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA6114040 |
| Cellosaurus | CVCL_YC27 |
| Wikidata | Q93561140 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | No |
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA6114041 |
Ethics
Also have a look at the ethics information for the parental line
GIBHi002-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
GIBHi002-A.
|
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| GATA3 |
Yes |
| GATA6 |
Yes |
| RXRG |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| SNAI2 |
Yes |
| HAND1 |
Yes |
| CDX2 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| PAX6 |
Yes |
| SOX1 |
Yes |
| MAP2 |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.